caa a22 4500 445338741 CHVBK 20180317142804.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1245/s10434-011-1806-0 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1806-0 Sarcoma Lung Metastases Treated with Percutaneous Radiofrequency Ablation: Results from 29 Patients [Elektronische Daten] [J. Palussière, A. Italiano, E. Descat, S. Ferron, F. Cornélis, A. Avril, V. Brouste, B. Bui] Purpose: We aimed to determine safety and efficacy of radiofrequency ablation (RFA) in the treatment of lung metastases arising from sarcoma. Methods: Between 2002 and 2009, 29 patients (mean age 51years) treated for metastatic sarcoma with a maximum of 5 lung metastases treatable with RFA were followed prospectively. The end points were local efficacy (assessed by computed tomography during the follow-up period), complications, and survival (overall and disease-free). Results: A total of 47 metastases were treated with RFA. Median follow-up time was 50months (range 28-72months). Pneumothorax was the most frequent complication and occurred in 68.7% of the procedures. The 1- and 3-year survival rates were 92.2% (95% confidence interval [CI] 0.73-0.98) and 65.2% (95% CI 0.42-0.81), respectively. Disease-free survival was 7months (95% CI 3.5-10). Five recurrences on RFA sites were noted during follow-up. Conclusions: RFA is safe and efficient in the treatment of lung metastasis originating from sarcomas. RFA may provide a low-morbidity alternative to surgery, being less invasive and preserving the patient's ability to undergo possible repeat operations. Society of Surgical Oncology, 2011 Palussière J. Department of Radiology, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut Italiano A. Department of Medical Oncology, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut Descat E. Department of Radiology, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut Ferron S. Department of Radiology, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut Cornélis F. Department of Radiology, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut Avril A. Department of Surgery, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut Brouste V. Clinical and Epidemiological Research Unit, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut Bui B. Department of Medical Oncology, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut Annals of Surgical Oncology Springer-Verlag 18/13(2011-12-01), 3771-3777 1068-9265 18:13<3771 2011 18 10434 https://doi.org/10.1245/s10434-011-1806-0 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1806-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Palussière J. Department of Radiology, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut NATIONALLICENCE 700 1- Italiano A. Department of Medical Oncology, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut NATIONALLICENCE 700 1- Descat E. Department of Radiology, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut NATIONALLICENCE 700 1- Ferron S. Department of Radiology, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut NATIONALLICENCE 700 1- Cornélis F. Department of Radiology, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut NATIONALLICENCE 700 1- Avril A. Department of Surgery, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut NATIONALLICENCE 700 1- Brouste V. Clinical and Epidemiological Research Unit, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut NATIONALLICENCE 700 1- Bui B. Department of Medical Oncology, Institut Bergonié, Regional Cancer Center, Bordeaux, France aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/13(2011-12-01), 3771-3777 1068-9265 18:13<3771 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer